



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 61954

Title: Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacy

Reviewer's code: 03550401

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Argentina

Manuscript submission date: 2020-12-23

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-01-11 08:08

Reviewer performed review: 2021-01-13 05:26

Review time: 1 Day and 21 Hours

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent [] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) <input checked="" type="checkbox"/> Minor revision [] Major revision [] Rejection
Re-review	<input checked="" type="checkbox"/> Yes [] No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous [] Onymous Conflicts-of-Interest: [] Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The author showed a very interesting work, who summarizes the safety and efficacy of statins use in patients with cirrhosis. The author summarized four factors related to the safety of using statins in patients with liver cirrhosis, mainly including dose, type, drug-drug interactions and statin metabolism and/or transport activities. And muscle and liver injury were the main proven adverse events, which were associated with the severity of liver function and the dosage of statin. The author shown increasing evidence from preclinical and clinical studies indicates that the use of statins may have a potentially beneficial effect on the natural history of liver cirrhosis and portal hypertension. At last, the author concluded that in patients with compensated liver cirrhosis, the dose of simvastatin is 20 mg/day, and simvastatin should not be given to patients with an Model for End-stage Liver Disease score > 12 or Child-Pugh C grade.

Major: The author classified the effectiveness of statins into observational studies and randomized controlled studies to explain, but in the following description, they classified according to the occurrence of infection and hepatocellular carcinoma. We hope that the author can classify and elaborate according to different ending points (such as portal pressure, complications including (bleeding, SBP, etc.), risk of cirrhosis decompensation, and risk of death...). Minor: It is more appropriate to replace liver fibrosis with cirrhosis in the keywords.



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 61954

Title: Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacy

Reviewer's code: 02444986

Position: Editorial Board

Academic degree: MD

Professional title: Academic Research, Doctor, Professor, Research Scientist

Reviewer's Country/Territory: Turkey

Author's Country/Territory: Argentina

Manuscript submission date: 2020-12-23

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-01-07 11:49

Reviewer performed review: 2021-01-19 13:43

Review time: 12 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Authors reviewed the current literature from the point of safety and effectiveness of statin treatment in patients with cirrhosis. My comments: *table1: the phrase of "In Bold Drugs of Clinical use in Argentina " should be omitted, and table should be modified accordingly. *the section titled as "our experience" should be extensively shortened. Whether the data was or was not published before must be stated. If the data was not published before, this section must be omitted, and submitted as another manuscript. *the manuscript must be edited for the grammar and format. Some parts of editing can be found in the attached file.



RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 61954

Title: Addition of statins to the standard treatment in patients with cirrhosis: Safety and efficacy

Reviewer's code: 03550401

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Argentina

Manuscript submission date: 2020-12-23

Reviewer chosen by: Chen-Chen Gao

Reviewer accepted review: 2021-03-01 03:43

Reviewer performed review: 2021-03-01 04:03

Review time: 1 Hour

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent [] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) [] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous [] Onymous Conflicts-of-Interest: [] Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

The author showed a very interesting work, who summarizes the safety and efficacy of statins use in patients with cirrhosis. We agree to accept and publish without any other comments.